Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series) - Image 1

£75.00

CRC Press Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)

Name: Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)
Brand: CRC Press
Price: 75.0 GBP
Availability: InStock

Law

It has never been this cheap. We have no record of a lower price.

£75 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 71 days · 71 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 71 days • 1 price levels

Days at Price

Price Analysis

Most common price: £75 (71 days, 100.0%)

Price range: £75 - £75

Price levels: 1 different prices over 71 days

Description

Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment. The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule’s journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies. The book also focuses on a molecule’s entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety. Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.

Key Features

Used Book in Good Condition

Product Specifications

Brand: CRC Press
Format: hardcover
ASIN: 1439867941
Category: Books > Subjects > Business, Finance & Law > Law
Domain: Amazon UK
Release Date: 27 November 2013
Listed Since: 13 February 2012

Barcode

No barcode data available

CRC Press Benefit-Risk Assessment in Pharmaceutical Research and Development (Chapman & Hall/CRC Biostatistics Series)

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Key Features

Product Specifications

Barcode

Similar Products You Might Like

Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy

Theory of Drug Development: 61 (Chapman & Hall/CRC Biostatistics Series)

Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)

Statistics In the Pharmaceutical Industry: 14 (Chapman & Hall/CRC Biostatistics Series)

Medical Writing in Drug Development: A Practical Guide for Pharmaceutical Research

Real-World Evidence in a Patient-Centric Digital Era (Chapman & Hall/CRC Biostatistics Series)

Real-World Evidence in a Patient-Centric Digital Era (Chapman & Hall/CRC Biostatistics Series)

Pharmaceutical Statistics: MBSW 39, Muncie, Indiana, USA, May 16-18, 2016: 218 (Springer Proceedings in Mathematics & Statistics, 218)

Biosimilars and Interchangeable Biologics: Strategic Elements

Statistical Methods in Biomarker and Early Clinical Development

Quantitative Decisions in Drug Development (Springer Series in Pharmaceutical Statistics)

Quantitative Decisions in Drug Development (Springer Series in Pharmaceutical Statistics)

Global New Drug Development: An Introduction (ULLA Series in Pharmaceutical Sciences)

Pharmaceutical Statistics Using SAS: A Practical Guide (SAS Press)

Drug-Drug Interactions for Therapeutic Biologics

Propelling Innovation in New Drugs: Recommendations & Considerations (Pharmacology-Research, Safety Testing and Regulation)

Global Issues in Pharmaceutical Marketing